A 30 YEAR JOURNEY
            WITH A RELENTLESS
            FOCUS ON SCIENCE

            OUR HISTORY

            1988

            Leonard S. Schleifer, MD, PhD: Founder of Regeneron

            Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College

            1989

            George D. Yancopoulos, MD, PhD a molecular immunologist launched Regeneron in 1989.

            George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, launches Regeneron

            1990

            Science publishes our first paper in 1990, which becomes the most highly cited neurobiology paper of the year.

            Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

            We announce a collaboration to develop neurotrophic factors

            1991

            REGN stock begins trading publicly on the NASDAQ in 1991

            REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

            1992

            Clinical development of Regeneron's first investigational drug began in 1992.

            Clinical development of our first investigational drug, a neurotrophic factor, begins

            1993

            Regeneron acquired space for a drug manufacturing facility in 1993.

            We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

            1995

            P. Roy Vagelos, MD becomes Chairman of the Board in 1995.

            Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

            Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

            1997

            Phase 3 trial of first neurotrophic factor does not achieve primary endpoint in 1997.

            The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

            1999

            George Yancopoulos, MD, PhD becomes 11th most highly cited scientists in 1999.

            George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

            2000

            ARCALYST injection begins clinical exploration in 2000.

            ARCALYST? (rilonacept) Injection, our first Trap technology, begins clinical exploration

            2003

            First paper on VelociGene? is published in 2003.

            Our first paper on VelociGene? is published, introducing the world to our proprietary Veloci technologies

            We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

            2004

            EYLEA injection begins clinical development in 2004.

            EYLEA? (aflibercept) Injection begins clinical development

            2006

            Regeneron's first fully human antibody enters clinical development in 2006.

            A collaboration with Bayer HealthCare focuses on developing EYLEA? (aflibercept) Injection outside the U.S.

            Sarilumab, our first fully human antibody, enters clinical development

            2007

            Collaboration with Sanofi using VelocImmune? technology platform in 2007

            A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune? technology platform

            2008

            FDA approval of ARCALYST injection in 2008

            The FDA approves our first medicine, ARCALYST? (rilonacept) Injection

            2009

            Regeneron hires its 1000th employee in 2009.

            We expand and extend our antibody collaboration with Sanofi

            PRALUENT? (alirocumab) Injection begins clinical development

            We hire our 1,000th employee and move into new buildings on our Tarrytown campus

            2010

            Regeneron begins to sponsor BioBus in 2010.

            We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

            2011

            EYLEA Injection is FDA approved in 2011.

            The FDA approves EYLEA? (aflibercept) Injection for its first indication

            Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year?

            2012

            Named biotech company of the year in 2012

            The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

            Scrip Intelligence names us Biotech Company of the Year

            2013

            Regeneron office opens in Dublin, Ireland in 2013.

            We announce the first recipients of our annual Regeneron Prize for Creative Innovation

            Our European business office opens in Dublin, Ireland

            Scrip Intelligence names Len and George as the "Management Team of the Year"

            2014

            Regeneron Genetics Center launches in 2014.

            The Regeneron Genetics Center, a new human genetics initiative, officially launches

            The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

            We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

            We begin building our first ex-U.S. IOPS site in Limerick, Ireland

            2015

            PRALUENT Injection received FDA approval in 2015.

            The FDA approves PRALUENT? (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

            We launch a major new immuno-oncology collaboration with Sanofi

            We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

            2016

            Regeneron becomes new title sponsor for the Science Talent Search in 2016.

            We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

            2017

            DUPIXENT Injection is FDA approved in 2017.
            KEVZARA Injection is FDA approved in 2017.

            The FDA approves DUPIXENT? (dupilumab) Injection, our fifth FDA-approved medicine

            FDA approves KEVZARA? (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody

            Recognized on the Civic 50 list of most community-minded companies in the United States

            2018

            Libtayo Injection receives FDA approval in 2018.Libtayo Injection receives FDA approval in 2018.DUPIXENT Injection is FDA approved for a new indication in 2018.

            2018 marks the thirtieth anniversary of Regeneron’s founding

            FDA approves Libtayo? (cemiplimab-rwlc) Injection, our seventh FDA-approved medicine

            The FDA approves a new indication for DUPIXENT? (dupilumab) Injection

            2019

            Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies; also included as one of Forbes’ “Most JUST Companies,” Newsweek’s “Most Responsible Companies” and the Civic 50 list of most-community minded companies in the U.S.

            The PALM clinical trial for Ebola patients in the Democratic Republic of Congo is stopped early after our investigational medicine shows superiority to the previous standard of care.

            The FDA and European Commission approves new indications for EYLEA? (aflibercept) injection, DUPIXENT? (dupilumab) injection, Libtayo? (cemiplimab) injection and Praluent? (alirocumab) injection.

            Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education.

            Society for Science & the Public announces Regeneron as new sponsor of the International Science and Engineering Fair.

            OUR HISTORY

            1988

            Leonard S. Schleifer, MD, PhD: Founder of Regeneron

            Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College

            1989

            George D. Yancopoulos, MD, PhD a molecular immunologist launched Regeneron in 1989.

            George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, launches Regeneron

            1990

            Science publishes our first paper in 1990, which becomes the most highly cited neurobiology paper of the year.

            Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

            We announce collaboration to develop neurotrophic factors

            1991

            REGN stock begins trading publicly on the NASDAQ in 1991

            REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

            1992

            Clinical development of Regeneron's first investigational drug began in 1992.

            Clinical development of our first investigational drug, a neurotrophic factor, begins

            1993

            Regeneron acquired space for a drug manufacturing facility in 1993.

            We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

            1995

            P. Roy Vagelos, MD becomes Chairman of the Board in 1995.

            Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

            Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

            1997

            Phase 3 trial of first neurotrophic factor does not achieve primary endpoint in 1997.

            The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

            1999

            George Yancopoulos, MD, PhD becomes 11th most highly cited scientists in 1999.

            George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

            2000

            ARCALYST injection begins clinical exploration in 2000.

            ARCALYST? (rilonacept) Injection, our first Trap technology, begins clinical exploration

            2003

            First paper on VelociGene? is published in 2003.

            Our first paper on VelociGene? is published, introducing the world to our proprietary Veloci technologies

            We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

            2004

            EYLEA injection begins clinical development in 2004.

            EYLEA? (aflibercept) Injection begins clinical development

            2006

            Regeneron's first fully human antibody enters clinical development in 2006.

            A collaboration with Bayer HealthCare focuses on developing EYLEA? (aflibercept) Injection outside the U.S.

            Sarilumab, our first fully human antibody, enters clinical development

            2007

            Collaboration with Sanofi using VelocImmune? technology platform in 2007

            A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune? technology platform

            2008

            FDA approval of ARCALYST injection in 2008

            The FDA approves our first medicine, ARCALYST? (rilonacept) Injection

            2009

            Regeneron hires its 1000th employee in 2009.

            We expand and extend our antibody collaboration with Sanofi

            PRALUENT? (alirocumab) Injection begins clinical development

            We hire our 1,000th employee and move into new buildings on our Tarrytown campus

            2010

            Regeneron begins to sponsor BioBus in 2010.

            We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

            2011

            EYLEA Injection is FDA approved in 2011.

            The FDA approves EYLEA? (aflibercept) Injection for its first indication

            Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year?

            2012

            Named biotech company of the year in 2012

            The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

            Scrip Intelligence names us Biotech Company of the Year

            2013

            Regeneron office opens in Dublin, Ireland in 2013.

            We announce the first recipients of our annual Regeneron Prize for Creative Innovation

            Our European business office opens in Dublin, Ireland

            Scrip Intelligence names Len and George as the "Management Team of the Year"

            2014

            Regeneron Genetics Center launches in 2014.

            The Regeneron Genetics Center, a new human genetics initiative, officially launches

            The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

            We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

            We begin building our first ex-U.S. IOPS site in Limerick, Ireland

            2015

            PRALUENT Injection received FDA approval in 2015.

            The FDA approves PRALUENT? (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

            We launch a major new immuno-oncology collaboration with Sanofi

            We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

            2016

            Regeneron becomes new title sponsor for the Science Talent Search in 2016.

            We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

            2017

            DUPIXENT Injection is FDA approved in 2017.

            The FDA approves DUPIXENT? (dupilumab) Injection, our fifth FDA-approved medicine

            FDA approves KEVZARA? (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody

            Recognized on the Civic 50 list of most community-minded companies in the United States

            2018

            2018 marks the thirtieth anniversary of Regeneron’s founding

            FDA approves Libtayo? (cemiplimab-rwlc) , our seventh FDA-approved medicine

            The FDA approves a new indication for DUPIXENT? (dupilumab) Injection

            2019

            Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies; also included as one of Forbes’ “Most JUST Companies,” Newsweek’s “Most Responsible Companies” and the Civic 50 list of most-community minded companies in the U.S.

            The PALM clinical trial for Ebola patients in the Democratic Republic of Congo is stopped early after our investigational medicine shows superiority to the previous standard of care.

            The FDA and European Commission approves new indications for EYLEA? (aflibercept) injection, DUPIXENT? (dupilumab) injection, Libtayo? (cemiplimab) injection and Praluent? (alirocumab) injection.

            Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education.

            Society for Science & the Public announces Regeneron as new sponsor of the International Science and Engineering Fair.

            色老大欧美大炮香蕉在线播放